AI MARKET SCANNING

Coherus Oncology, Inc.

📅 Next Catalyst: Nov 05, 2026 (🌙 Close) 🏛️ NASDAQ 📁 Healthcare 🏭 Biotechnology
AVG HISTORICAL GAP -3.19%
MAX GAP RECORD -22.60%
🔒 PRO INSTITUTIONAL AI PREDICTIVE WIN RATE
94.2%
REVEAL PRO DIRECTION ⚡

SENTINEL HISTORICAL GAP VIEWER

// $CHRS
📊 1-YEAR TIMELINE (GAPS PLOTTED) 🔮 SIMULATE SETUP 🔒
Bullish Opening Gap Bearish Opening Gap T-1 Close Baseline

CATALYSTS & GAP HISTORY

Nov 05, 2026 Earnings Release 2026-11-05 (AFTER CLOSE (21:00)) 🔮 UPCOMING 🔒
Aug 05, 2026 Earnings Release 2026-08-05 (AFTER CLOSE)
-4.48%
May 11, 2026 Earnings Release 2026-05-11 (AFTER CLOSE)
-10.26%
Mar 09, 2026 Earnings Release 2026-03-09 (AFTER CLOSE)
-3.63%
Nov 06, 2025 Earnings Release 2025-11-06 (AFTER CLOSE)
-9.40%
Aug 07, 2025 Earnings Release 2025-08-07 (AFTER CLOSE)
-1.13%
May 12, 2025 Earnings Release 2025-05-12 (AFTER CLOSE)
-14.02%
Mar 10, 2025 Earnings Release 2025-03-10 (AFTER CLOSE)
+0.00%

VOLATILITY & GAP BIAS

AVG GAP MOVE 7.9%
Bullish Gaps (4)
Bearish Gaps (9)
Neutral / Flat (1)

QUANTITATIVE LIVE RADAR BLOTTER

Algorithmic execution stream for $CHRS

EXECUTIONS0 LOGS
STATUS🔒 ENCRYPTED
Execution Date Strategy & Setup Direction Execution Range Hold Time Net PnL
Radar monitoring: awaiting next setup.
🔒 Real-Time Strategy Telemetry Protected

Exact execution levels, Trailing Stops, and live bot signals are reserved for PRO members.

UNLOCK LIVE RADAR ⚡

📖 Intelligence Summary

Coherus Oncology, Inc., a biopharmaceutical company, researches, develops, and commercializes immunotherapies to treat cancer in the United States. The company develops UDENYCA, a biosimilar to Neulasta, a long-acting granulocyte-colony stimulating factor; LOQTORZI, a novel next-generation programmed death receptor-1 inhibitor; and Casdozokitug, an investigational recombinant human immunoglobulin isotype (IgG1) monoclonal antibody…

NEXT UPCOMING PREDICTIVE SIGNAL
STRONG BUY / TARGET +35%
🔓 REVEAL AI SIGNAL & TARGETS ↗